Marker sequences for diagnosing and stratifying systemic sclerosis patients
The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.
1. A panel of markers for use with systemic sclerosis (SSc), comprising at least two different markers attached to a solid substrate, wherein each of the markers have a peptide sequence selected independently of one another from any one of SEQ ID NOs: 1-10, 13 and 15-18.
2. The panel of claim 1 , wherein at least one of the markers has a length of no more than 25 amino acids.
3. The panel of claim 1 , wherein at least one of the markers has a length of no more than 15 amino acids.
4. The panel of claim 1 , wherein the markers comprise a binding region.
5. The panel of claim 1 , wherein the markers comprise an epitope.
6. A diagnostic device or a test kit for use with SSc, comprising
a panel of markers comprising at least two different markers attached to a solid substrate, wherein each of the markers have a peptide sequence selected independently of one another from the peptide sequences of SEQ ID NO: 1-10, 13, and 15-18.
7. A composition comprising at least one marker from the panel of markers of claim 1 .
8. The composition of claim 7 , wherein the composition is a pharmaceutical composition for specific application in SSc.
9. The panel of claim 1 , wherein the markers have the peptide sequences selected independently from any one of SEQ ID NOs: 1, 3, 4, and 6.
10. The panel of claim 1 , wherein the markers bind to autoantibodies that are present during the course of development, establishment, or therapy of SSc.
11. The panel of claim 10 , wherein the markers bind to autoantibodies that are up-regulated or down-regulated during the course of development, establishment, or therapy of SSc.